Takeda Pharmaceutical Co. will get to arbitrate claims by a plaintiff that accused the company of delaying the generic ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX) shares, currently trading at $148.19, maintained a positive outlook as Stifel ...

Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.

Plasma-derived therapies are essential for treating a wide range of conditions, including immune deficiencies, bleeding ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

The comments mark the latest in a number of trade-related threats unleashed by Trump in recent days. Trump said he plans to ...

Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NBIX stock, giving a Buy rating on January 24.Invest with ...

U.S. President Donald Trump plans to impose tariffs on imported computer chips, pharmaceuticals and steel, he said on Monday, ...

Takeda is taking back the home license for a phase 3-ready depression drug as part of an amendment to its multi-asset ...

BioMed Realty, one of the biggest labspace owners in the Boston area, recently acquired 215 First St., 150 Second St. and 11 ...

An announcement from Neurocrine ( ($NBIX) ) is now available. On January 24, 2025, Neurocrine Biosciences announced an amendment to its Exclusive ...

Lasell University president Eric Turner is hoping that many Lasell students will find success in the real world by spending ...